NVO vs AMGN — which stock performed better?

Novo Nordisk (NVO) versus Amgen (AMGN), Health Care, on 2026-11-09.

Result

Novo Nordisk (NVO) performed better on 2026-11-09. NVO moved 0.630%, AMGN moved 0.020%.

Why these two companies

Novo Nordisk raised its full-year outlook on November 4, 2026 after a stronger third quarter, with CEO Mike Doustdar detailing plans to launch the CagriSema obesity shot in early 2027, yet NVO shares still fell nearly 4.5% on pricing and competition worries. The same week, Amgen stock pushed toward an all-time high as its own obesity contender, MariTide, advanced its bid for a slice of what Bloomberg's November 2, 2026 feature called a "$120 Billion Obesity Market." With both drugmakers posting fresh quarterly numbers days apart but getting opposite market reactions, this is a timely head-to-head in a sector where obesity-drug leadership is being actively contested.

The research

Novo Nordisk makes the Ozempic and Wegovy medicines that helped start the modern weight-loss drug boom, while Amgen is a much older, more diversified drugmaker now racing to join that market with its own experimental shot called MariTide. Someone might like Novo Nordisk because it just raised its full-year sales forecast and its shares are trading far below where they were a year ago, which some investors see as a discount on the market leader. Someone might like Amgen because its shares recently hit a new high and its business is more spread out across many products, so it is not as dependent on any single drug succeeding.

One thing to keep in mind with Novo Nordisk is that even after good results, its stock dropped on worries about how it will price its new pill and how fast it can roll out its next-generation treatment. One thing to keep in mind with Amgen is that a lot of investor excitement is riding on a drug that is still being tested and has not yet been approved, so disappointing trial news could hit the stock hard.

Both companies reported their latest quarterly results within a day of each other, and both beat expectations, yet the stocks moved in opposite directions. That makes this matchup less about which company is doing better right now and more about which story investors trust more going forward: the proven leader working through growing pains, or the ambitious challenger still waiting to prove itself.